The official Imperial launch of the Apollo Therapeutics took place on 6 October. Apollo Therapeutics is a collaboration between three global pharmaceutical companies (GSK, J&J and AZ) and three Universities – Imperial, Cambridge and UCL. This is the first time that three global pharmaceutical companies and the tech transfer offices of three world leading universities has come together to form a joint enterprise resulting in a truly innovative venture aimed driving forward therapeutic innovation. It is a £40 million fund to drive therapeutic innovation aims to to significantly improve the speed and potential of university research being translated into novel medicines. Apollo will support translational research, shaping projects at an early stage to optimise discovery and delivery of new breakthrough treatments for onward development.
The launch event saw more than 75 Imperial academics, industry collaborators and Apollo representatives coming tog ether. The event was opened by Professor James Stirling and the scheme was introduced by Ian Tomlinson (Apollo Therapeutics Chairman) and Richard Butt (Apollo Therapeutics CEO). A panel Q&A session with The Apollo Leadership team together with Professor Jonathan Weber and Dr Mene Pangalos (Executive Vice President at AstraZeneca) discussed the opportunities for the College presented by the venture.
A call for biologics proposals is currently open; for more information about the scheme please see: http://apollotherapeutics.com/
Dr Sarah Wagstaffe
Head of Research Strategy
Faculty of Medicine